At a glance
ClinicalIndex Comparison RecordN/ACompleted· 50 enrolled
Drug / intervention
Self administrationprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Self Administration of Subcutaneous Depot Medroxyprogesterone Acetate: A Pilot Observational Study of Feasibility and Acceptability
In Brief
An observational study evaluating Self administration for Fertility. Completed, enrolled 50 participants across 2 sites.
Detailed Summary
The purpose of this study is to assess continuation rates and patient satisfaction with self administration subcutaneous depot medroxyprogesterone acetate.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsFertility
CountriesUnited States
CollaboratorsPfizer, Planned Parenthood Federation of America
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2008
Enrollment StartMay 2010
Primary CompletionJun 2011
TodayJul 2026
First PostedOct 10, 2008
Enrollment StartMay 1, 2010
Primary CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 17.7 years ago
Interventions
Self administrationprocedure
Subjects will self administer injections of 104 mg of the subcutaneous formulation of depot medroxyprogesterone acetate (depo-subQ provera 104).